跳轉至內容
Merck
全部照片(2)

重要文件

32097

Supelco

依托考昔

VETRANAL®, analytical standard

同義詞:

5-氯-3-[4-(甲磺酰基)苯基]-2-(2-甲基-5-吡啶基)吡啶, 5-氯-6′-甲基-3-[4-(甲磺酰基)苯基]]-2,3′-联吡啶

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C18H15ClN2O2S
CAS號碼:
分子量::
358.84
Beilstein:
8073797
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

analytical standard

品質等級

產品線

VETRANAL®

儲存期限

limited shelf life, expiry date on the label

技術

HPLC: suitable
gas chromatography (GC): suitable

應用

forensics and toxicology
pharmaceutical (small molecule)
veterinary

格式

neat

儲存溫度

2-8°C

SMILES 字串

CC1=NC=C(C2=C(C3=CC=C(S(C)(=O)=O)C=C3)C=C(Cl)C=N2)C=C1

InChI

1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3

InChI 密鑰

MNJVRJDLRVPLFE-UHFFFAOYSA-N

基因資訊

human ... PTGS2(5743)

尋找類似的產品? 前往 產品比較指南

一般說明

依托考昔是一种非甾体类环加氧酶-2(COX-2)选择性抗炎药,主要用于骨关节炎和类风湿性关节炎患者的治疗。

應用

依托考昔已被用作参考标准品,用于通过液相色谱-串联质谱-常压化学电离分析法(LC-APCI/MS/MS)检测人血浆中的依托考昔。
有关合适仪器技术的更多信息,请参考产品′s分析证书。如需进一步支持,请联系技术服务。

法律資訊

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

象形圖

Skull and crossbones

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 2 Dermal - Acute Tox. 4 Oral

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類(WGK)

WGK 3


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Shruti Setia et al.
Molecular and cellular biochemistry, 366(1-2), 89-99 (2012-03-14)
Roles of cyclooxygenase (COX) enzyme and intrinsic pathway of apoptosis have been explored for the chemopreventive effects of non-steroidal anti-inflammatory drugs (NSAIDs) on 9,10-dimethyl benz(a)anthracene (DMBA)-induced lung cancer in rat model. 16 weeks after the administration of DMBA, morphological analysis
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF
Health Technology Assessment (Winchester, England), 12(11), 1-278 (2008)
V Dahl et al.
Acta anaesthesiologica Scandinavica, 56(1), 95-101 (2011-11-23)
Many studies have demonstrated that either COX-2 antagonists or glucocorticoids are efficient analgesics after orthopaedic surgery. We wanted to evaluate if the combination of these two drugs was better than one drug alone when added to paracetamol, local anaesthesia, and
Jody K Takemoto et al.
Clinical pharmacokinetics, 47(11), 703-720 (2008-10-09)
The NSAID etoricoxib is a selective inhibitor of cyclo-oxygenase 2 (COX-2), approved for treatment of patients with chronic arthropathies and musculoskeletal and dental pain. The rate of absorption of etoricoxib is moderate when given orally (the maximum plasma drug concentration
I L Meek et al.
European journal of clinical pharmacology, 69(3), 365-371 (2012-08-15)
Nonsteroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid (ASA) are often prescribed concurrently in patients with nociceptive pain and cardiovascular comorbidity. NSAIDs and ASA inhibit the same COX-enzymes, and thus may interact. ASA's cardioprotective antiplatelet effect is entirely COX-1 dependent. NSAIDs

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務